ETON · Eton Pharmaceuticals, Inc.
$58.86
+18.06 (+44.26%)
At close · Aug 14
Market Cap
$1.68B
Shares
28.58M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Sean Brynjelsen | President and Chief Executive Officer | $1,747,045 |
| James Gruber | Chief Financial Officer | $785,140 |
| David Krempa | Chief Business Officer | $719,080 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Sean Brynjelsen | President and Chief Executive Officer | $2,119,541 |
| David Krempa | Chief Business Officer | $916,805 |
| James Gruber | Chief Financial Officer | $712,845 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Sean Brynjelsen | President and Chief Executive Officer | $2,092,292 |
| James Gruber | Chief Financial Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Sean Brynjelsen | President and Chief Executive Officer | $2,011,293 |
| Wilson Troutman | Chief Financial Officer | $906,112 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Sean Brynjelsen | President and Chief Executive Officer | $1,946,408 |
| Wilson Troutman | Chief Financial Officer | $864,627 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Sean Brynjelsen | President and Chief Executive Officer ^^ | $493,022 |
| Wilson Troutman | Chief Financial Officer | $296,552 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Danka Radosavljevic | Chief Operating Officer | Appointed | 2026-08-04 |
| Judith Matthews | Chief Financial Officer | Appointed | 2026-04-16 |
| David Krempa | Chief Business Officer | Appointed | 2023-03-01 |
| Wilson Troutman | Chief Financial Officer, Corporate Secretary and Treasurer | Retired | 2022-04-11 |
| James Gruber | Chief Financial Officer, Corporate Secretary and Treasurer | Appointed | 2022-04-11 |
Key facts
CIK
1710340
CUSIP
29772L108
13F (30d)
156 filings
154 filers
Visit website
Investor relations